Centaur Biopharmaceutical Services, a wholly-owned subsidiary of Kindred Biosciences, announced an expanded agreement between KindredBio and Vaxart under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates.
Centaur is a full-service contract development and manufacturing organization that specializes in protein-based biologics and virus-based products. Centaur's capabilities span cell line development, process development, analytical development, process characterization, clinical manufacturing, and commercial manufacturing including aseptic fill-and-finish.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"With this major contract, we are pleased to establish Centaur as a trusted partner for contract manufacturing," said Centaur's Chief Commercial Officer, Russell Harris. "We are excited to assist in this important project."
Under the terms of the expanded agreement, the California plant will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors and the Kansas plant will be responsible for manufacturing at 2000L scale in its single use bioreactors.